Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function

Noora Ristiniemi1, Caroline Savage2, Laila Bruun3, Kim Pettersson1, Hans Lilja4,5 and Anders Christensson3

1Department of Biotechnology, University of Turku, Turku, Finland, 2Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 3Departments of Clinical Sciences, Division of Nephrology and Transplantation, Lund University, Skåne University Hospital, Malmö, Sweden, 4Department of Clinical Laboratories, Surgery (Urology), and Medicine (GU-Oncology), Memorial Sloan-Kettering Cancer Center, New York, NY, USA and 5Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden

Correspondence and offprint requests to: Anders Christensson; E-mail: anders.christensson@med.lu.se

Abstract

Background. Elevated cystatin C in blood reflects impaired glomerular filtration rate (GFR), but current cystatin C assays, based on polyclonal antibodies and immunoturbidimetric or nephelometric detection, have several limitations. We evaluated a new immunoassay based on monoclonal antibodies in samples from patients with and without chronic kidney disease (CKD).

Methods. The study enrolled 170 men without known CKD (Group A) and 104 men with CKD (Group B). All patients were assessed with iohexol clearance, plasma creatinine and plasma cystatin C by a conventional particle-enhanced immunoturbidimetric assay (PETIA) and by the new double monoclonal assay. In Group A, three serial blood draws were performed at median intervals of 4 h and 12 days between samples, to also allow assessments of the variability in cystatin C values with the new assay. Concordance correlation coefficients and the 95% limits of agreement were used to estimate the agreement of reciprocal cystatin C and reciprocal creatinine with iohexol clearance.

Results. Median iohexol clearance (mL/min/1.73 m²) was 81 [interquartile range (IQR) 70, 92] in Group A and 23 (IQR 16, 34) in Group B. The concordance correlation with GFR for the new cystatin C assay compared to the established assay was similar in Group A (0.441 versus 0.465) but higher in Group B (0.680 versus 0.593). Cystatin C measured by both assays exhibited closer agreement with GFR than creatinine. The agreement between the two cystatin C assays was high, with concordance correlations of 0.815 in Group A and 0.935 in Group B. Compared to the conventional assay, the new assay tended to yield lower values of cystatin C at the low end of the range in Group A. The new cystatin C assay exhibited small intra-individual variability across serial samples (coefficient of variation ≤6%).

Conclusions. In this first clinical evaluation, the new cystatin C assay performed similarly to the established PETIA in patients with normal GFR and better in patients with CKD. The new assay may offer an alternative to current commercial assays to detect and monitor impaired kidney function.

Keywords: creatinine; cystatin C; glomerular filtration rate; iohexol clearance; renal function

Introduction

Assessment of kidney function is important in clinical practice for determining overall health, selecting correct dosages for drugs cleared by the kidneys, preparing for therapeutic procedures and detecting acute and chronic kidney disease (CKD). Assessment of kidney function is also important because impaired kidney function is strongly associated with cardiac diseases [1–3]. Epidemiologic studies have shown that CKD in many countries has a prevalence of >10% [4] and that prevalence is rising [5]. However, the best index of kidney function, glomerular filtration rate (GFR), cannot be measured easily in clinical practice. Indirect estimation of GFR from serum creatinine has long been the only method practical for routine clinical testing, but serum creatinine has several limitations. Therefore, the recommended method for evaluating kidney function is to use the serum creatinine value in a formula that estimates GFR.

Cystatin C has many characteristics of an ideal endogenous GFR marker [6]. Several investigations have indicated that serum cystatin C is as good as or better than serum creatinine as a GFR marker in patients with native kidneys, especially in patients with mild or moderate reduction of GFR [7–10]. In a meta-analysis, serum cystatin...
C was superior to creatinine in measuring renal function both in children and adults [7]. However, there are conflicting results, and some investigators have not found cystatin C to be advantageous [11]. One possible reason for conflicting results on the relationship between GFR and cystatin C is that factors other than GFR may affect serum cystatin C levels [11–13]. Another possible reason is that some of the studies used samples that had been stored for a long period of time, which may have caused analytical problems. Nevertheless, the promising results on estimating renal function from cystatin C have led to the development of commercial assays, sold as reagent kits, which use polyclonal antibodies against cystatin C. Signal detection is based on light scattering in particle-enhanced turbidimetric and nephelometric immunoassays (PETIA and PENIA, respectively). However, the use of polyclonal antibodies can cause variation from batch to batch. In addition, the use of light scattering can render the assay susceptible to interfering factors such as lipemia, hemolysis and bilirubinemia. This interference is recognized on turbidimetric detection principles. Samples that have been stored may have other drawbacks in turbidimetric assays, such as opalescence from precipitated lipids.

A newly designed assay for cystatin C based on two monoclonal antibodies and time-resolved fluorescent detection [14] is potentially less prone to these forms of interference. The use of monoclonal instead of polyclonal antibodies makes the assay more uniform and stable. The monoclonal antibody combination in the new assay gives fast binding and good correlation (R = 0.949) with a PETIA assay from Roche (Basel, Switzerland). The new assay also demonstrates excellent linearity and a wide linear range in measuring cystatin C concentrations, covering all clinically relevant concentrations of cystatin C, and the assay measures highly similar concentrations of cystatin C in serum samples compared to anticoagulated plasma samples [14]. The imprecision of the new assay is also suggested to be low with a total imprecision of <5.6% [14]. The new assay for cystatin C is sensitive and therefore uses extensive sample dilution, which diminishes possible interference from the sample, particularly interference caused by heterophilic antibodies. In addition, a wash step prior to detection in the new assay removes blood components that could potentially interfere with signal detection.

The aim of this study was to evaluate the performance of the new assay in patients with normal and reduced kidney function. Results of new and established cystatin C assays and creatinine assays were compared to plasma clearance of iohexol, which we considered the gold standard for assessment of GFR.

Materials and methods

Patients and blood collection

Two groups of patients were used in these analyses: those with normal renal function (Group A) and those with slight to advanced renal dysfunc-

A new immunoassay for cystatin C 683

A new immunoassay for cystatin C based on two monoclonal antibodies and time-resolved fluorescent detection is potentially less prone to these forms of interference. The use of monoclonal instead of polyclonal antibodies makes the assay more uniform and stable. The monoclonal antibody combination in the new assay gives fast binding and good correlation (R = 0.949) with a PETIA assay from Roche (Basel, Switzerland). The new assay also demonstrates excellent linearity and a wide linear range in measuring cystatin C concentrations, covering all clinically relevant concentrations of cystatin C, and the assay measures highly similar concentrations of cystatin C in serum samples compared to anticoagulated plasma samples [14]. The imprecision of the new assay is also suggested to be low with a total imprecision of <5.6% [14]. The new assay for cystatin C is sensitive and therefore uses extensive sample dilution, which diminishes possible interference from the sample, particularly interference caused by heterophilic antibodies. In addition, a wash step prior to detection in the new assay removes blood components that could potentially interfere with signal detection.

The aim of this study was to evaluate the performance of the new assay in patients with normal and reduced kidney function. Results of new and established cystatin C assays and creatinine assays were compared to plasma clearance of iohexol, which we considered the gold standard for assessment of GFR.
because Group A and B represent distinct patient populations. All statistical analyses were conducted using Stata 10.0 (StataCorp, College Station, TX).

**Ethical considerations**

The study was approved by the regional ethics committee at Lund University, Sweden, LU 587-00, and all subjects provided written consent to participate in the study and to allow retrieval of information from medical records.

**Results**

Patient characteristics and renal function measurements for the two groups are shown in Table 1. Median age was 65 years in Group A (patients without known CKD) and 57 years in Group B (patients with CKD). Overall, cystatin C measurements were lower and more homogenous in Group A than in Group B. Iohexol clearance measurement showed a median GFR of 81 [range of 29–119, interquartile range (IQR) 70–92] mL/min/1.73 m² in Group A. This ‘normal renal function’ group included 49 participants (29%) with no CKD or Stage 1 CKD, 104 (61%) with Stage 2, 16 (9%) with Stage 3 and 1 (0.6%) with Stage 4. In Group B, median GFR measured from iohexol clearance was significantly lower at 23 (range 8–83, IQR 16–34) mL/min/1.73 m². In this group, four patients (4%) had Stage 2 CKD, 29 (28%) had Stage 3 CKD, 51 (49%) had Stage 4 and 20 (19%) had Stage 5.
Table 2 summarizes the concordance correlation coefficients and limits of agreement for 1/cystatin C and 1/creatinine compared to iohexol clearance. Overall, the agreement between cystatin C and the true GFR was higher in patients with renal disease (Group B) than in those with normal renal function (Group A). When the two cystatin C assays were compared with iohexol clearance in Group A, the conventional assay had a slightly higher concordance correlation than the new assay, whereas in Group B, the new assay had the higher concordance correlation. Both cystatin C assays tended to overestimate true GFR in both cohorts (Figures 1 and 2, Table 2), but both cystatin C assays exhibited better agreement with iohexol clearance than did creatinine in Group A and B (Figures 1–3). The lowest concordance correlation was shown between 1/creatinine and iohexol clearance. However, at low levels of renal function (GFR < 30), creatinine appeared to have better agreement with GFR (Figure 3).

Figure 4 shows the correlation plots for reciprocal plasma cystatin C values determined with the conventional and new cystatin C assays. The agreement between the two assays for cystatin C was high, with concordance correlation 0.815 in Group A and 0.935 in Group B. The new assay, compared to the conventional assay, tended to yield slightly higher values at the high end of 1/cystatin C (Figure 4). The increasing difference between the two methods for cystatin C at higher GFR is also seen in Bland Altman plots for Groups A and B (Figure 5a and b, respectively).

We summarized the variation of reciprocal cystatin C levels across different time points as the coefficient of variation measured with the new assay using serial blood samples obtained at three separate time points from the men in Group A (Table 3). The intraindividual coefficients of variation between the time points were low and relatively consistent. The mean (SD) variation in cystatin C as well as in reciprocal cystatin C was 6% (4%) between Time 1 and 3 and was 5% (4%) both between Time 1 and Time 2 and between Time 2 and Time 3.
that the intraindividual variation in cystatin C levels in strengthens the precision, reliability and clinical utility stability of the new assay as a diagnostic test and significant. This low short-term variability reflects not only the variation, was found to be small and clinically insignif-

In this study, the established cystatin C assay used for comparison was a PETIA. A recent investigation has suggested that PENIA may be more reliable than PETIA [21], which could limit the conclusion of our study. However, numerous studies with PETIA have shown a good correlation with GFR measured by standard methods [7, 22], and we also had true GFR values included in this study. Nevertheless, our results need to be confirmed in relation to a PENIA. Another possible limitation in comparative studies is that the conventional assays for cystatin C are not standardized. The lack of an international calibrator complicates the estimation of agreement of cystatin C values with true GFR since systematic differences in cystatin C levels between different assay technologies are known to exist and were seen in this study, especially at high levels of cystatin C. The difference between the conventional and the new method is interest-

### Discussion

Many studies have shown advantages of cystatin C over creatinine as a GFR marker. Although some studies have not shown such an advantage, almost none have shown better diagnostic performance for creatinine than for cystatin C. However, the established cystatin C assays have some methodologic weaknesses, such as susceptibility to interference from substances in blood, especially in samples that have been stored. Some of these methodologic weaknesses of the standard cystatin C assays are addressed by a recently developed highly sensitive assay for plasma cystatin C that uses two monoclonal antibodies [14], and the current report is the first clinical evaluation of this new assay. Here, we demonstrate that this new assay performs well compared to the conventional PETIA. In particular, we have demonstrated that the new assay performs better than the old assay in male patients with CKD. Cystatin C, with both assays, is superior to creatinine in correlation with iohexol clearance.

From our findings, that reciprocal cystatin C levels exhibited much better agreement with true GFR than reciprocal creatinine levels, we anticipate that subsequent development and use of an estimated glomerular filtration rate (eGFR) formula that is based on cystatin C, or possibly could incorporate both creatinine and cystatin C, would substantially improve the agreement with measured GFR. However, we did not use the published cystatin C-based eGFR formula, which was developed for use with the conventional assay [19], as the accuracy of the cystatin C-based eGFR formula would be biased in favor of the conventional assay and would not permit a fair comparison with the new cystatin C assay.

The concordance correlation coefficient with measured GFR was higher in the group of men with impaired renal function for all assessments, both cystatin C assays and creatinine. The reason for this is not completely clear, but formulas for eGFR also perform better in decreased GFR ranges than in the normal range [20]. It is well known that eGFR calculated by the modification of diet in renal disease formula underestimates GFR in the normal range by up to 30% but only by 6% in patients with CKD.

With the new cystatin C assay, intraindividual variability between time points, described as coefficients of variation, was found to be small and clinically insignificant. This low short-term variability reflects not only the stability of the new assay as a diagnostic test and strengthens the precision, reliability and clinical utility of cystatin C as a GFR marker but also suggests strongly that the intraindividual variation in cystatin C levels in

### Conclusion

In this first clinical evaluation, the new assay for cystatin C shows good agreement with the established conventional PETIA. In patients with CKD, it showed better agreement with true GFR than PETIA. These results imply that the new assay may be an alternative to the present commercial assays.

**Acknowledgements.** We thank Prof Anders Grubb for fruitful discussion. Dr Thomas Björk is acknowledged for his generous assistance in
collection of patient samples. We also thank Janet Novak, at Helix Editing, for assistance with editing of the manuscript, which was paid for by Lund University, and thank Pirjo Laaksonen, Susanna Rytkönen and Dr K-G Prütz for valuable help. We gratefully acknowledge HyTest Ltd and Innova Diagnostics for reagent and instrumentation support. This investigation was supported by the Fulbright Commission, the National Cancer Institute [P50-CA92629]; Swedish Cancer Society [3455]; Swedish Research Council [Medicine-20095]; the Sidney Kimmel Center for Prostate and Urologic Cancers; David H. Koch through the Prostate Cancer Foundation; the Medical Faculty at Lund University; Malmö University Hospital; Region Skåne; Fundación Federico SA.

Conflict of interest statement. None declared.

References


Received for publication: 22.12.10. Accepted in revised form: 19.5.11